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AbstrAct
Introduction Chronic inflammatory diseases such as 
eczema (also known as atopic dermatitis) have been 
inconsistently linked to cardiovascular disease and stroke 
in both mechanistic and epidemiological studies. There 
is a need to review the existing epidemiological data 
examining the association between eczema and major 
cardiovascular outcomes, including angina, myocardial 
infarction, coronary revascularisation, heart failure, cardiac 
arrhythmias, stroke and cardiovascular death, in order to 
improve our understanding of the comorbidities of eczema.
Methods and analysis We will systematically review 
population-based studies, including cohort, case–control 
and cross-sectional studies, reporting on the association 
between eczema and cardiovascular outcomes. We will 
search Medline, Embase and Global Health, from their 
date of inception to April 2017, using a comprehensive 
search strategy formulated with the help of a librarian. Two 
reviewers will independently screen titles and abstracts 
in duplicate, followed by independent data extraction 
and quality assessment. We will group studies by the 
cardiovascular outcome under study and synthesise 
them narratively. If sufficient numbers of homogeneous 
studies are returned, we will perform meta-analyses to 
obtain pooled effect estimates. Preferred Reporting Items 
for Systematic Review and Meta-Analysis will be used to 
inform the reporting of this study.
trial registration number CRD42017060359.
IntroductIon
Eczema is an inflammatory skin disease, tradi-
tionally considered a disease of childhood. 
However, eczema may affect around 10% of 
adults1 2 and the global prevalence of eczema 
is increasing.3 Concurrently, cardiovascular 
disease is fast becoming a significant cause 
of mortality and morbidity in both high-in-
come and low-income and middle-income 
countries. Chronic inflammatory conditions 
have been linked to cardiovascular disease, 
in diseases of varying aetiology, from psoriasis 
and rheumatoid arthritis to HIV.4–7
There are a number of lines of evidence 
supporting an association between eczema 
and cardiovascular disease. Mechanistic 
studies suggest that platelet dysfunction and 
decreased fibrinolysis may contribute to 
increased clotting in eczema.8 9 Severe eczema 
has been associated with increased incidence 
of coronary artery disease using cardiac CT 
angiography.10 In addition, treatments used 
for eczema may increase cardiovascular 
risk11 12; however, a likely limitation of the 
studies to be included in this review will be 
the likely strong collinearity between eczema 
severity and level of treatment. Factors such 
as confounding by severity could contribute 
to an observed increase in cardiovascular 
disease and stroke in eczema.
Epidemiological studies have inconsis-
tently linked eczema to cardiovascular risk 
factors, disease and stroke across different 
populations,13–16 while previous systematic 
reviews have found an association between 
eczema and risk factors for cardiovascular 
disease, including raised body mass index17 
and childhood type 1 diabetes.18 There is a 
need to review the existing epidemiolog-
ical data linking eczema to major cardio-
vascular outcomes in order to increase our 
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Protocol
strengths and limitations of this study
 ► This systematic review protocol is reported in line 
with the  Preferred Reporting Items for Systematic 
Review and Meta-Analysis Protocols guidelines.
 ► A systematic and broad search strategy planned 
with the help of a librarian attempts to identify all 
studies that meet the eligibility criteria.
 ► Two authors will independently assess search 
results using an online data management program 
to minimise bias and errors in screening, data 
extraction and quality assessment of studies.
 ► Despite an extensive search, it is still possible that 
relevant papers may have been missed.
 ► Studies may not systematically report all outcomes.
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understanding of the comorbidities of eczema, and to 
inform management and prevention strategies at an indi-
vidual and population level.
The primary objective of this systematic review is to 
ascertain the association between eczema and major 
cardiovascular outcomes, including angina, myocar-
dial infarction, coronary revascularisation, heart failure, 
cardiac arrhythmias, stroke and cardiovascular death, in 
population-based studies.
The secondary objectives of this review are to answer 
the following questions:
 ► Does the strength of the association between eczema 
and major cardiovascular outcomes increase as 
severity of eczema increases?
 ► Does treatment of eczema alter the risk of cardiovas-
cular outcomes (although it may not be possible to 
completely disentangle the effects of disease severity 
and treatment as those with severe disease are often 
defined by their treatment with systemic therapy)?
 ► Is the association between eczema and major cardi-
ovascular outcomes consistent across different 
countries?
 ► Does the association vary for different cardiovascular 
disease endpoints?
 ► Is there any modification of effect by age and gender?
Methods And AnAlysIs
eligibility criteria
Peer-reviewed, published studies in any language, from 
any year, are eligible to be included. Studies must be 
population-based, with an average age of participants >18. 
Studies may be cohort, case–control or cross-sectional 
designs, from any healthcare setting, with any length of 
follow-up. The exposure of interest is eczema (atopic 
dermatitis). The comparator will be people or person 
years without eczema. Outcomes are major cardiovascular 
outcomes, which will include angina, myocardial infarc-
tion, coronary revascularisation, heart failure, cardiac 
arrhythmias, stroke and cardiovascular death.
We will exclude case series (including retrospective 
clinic populations), ecological studies, reviews and 
studies in paediatric populations only. Studies of local-
ised or other types of eczema such a hand eczema, and 
seborrheic or contact dermatitis, are not eligible to be 
included.
literature search
We will search the following electronic databases from 
their date of inception to April 2017: Medline via Ovid, 
Embase via Ovid and Global Health. The search strategies 
were created by a researcher with medical and system-
atic review training, in conjunction with a librarian with 
expertise in searching the literature, and reviewed by 
all authors. Exclusion filters and limits will not be used 
in the search due to the risk that eligible studies may 
be inadvertently excluded. The Ovid Medline search 
strategy is available to view (see online supplementary 
appendix 1). We will also review the bibliographies of 
included studies, and contact experts in the field for 
relevant references.
selection of studies and data extraction
Covidence, an online literature reviewing data manage-
ment program, will be used to facilitate collaboration and 
data extraction between reviewers. All titles and abstracts 
resulting from the literature search will be uploaded 
to Covidence. Duplicates will be removed by AA. Two 
reviewers (AA and AMY) will independently screen 
titles and abstracts in duplicate. Full-text articles will be 
retrieved where studies fulfil inclusion criteria, or where 
there is any ambiguity of the study’s eligibility. Disagree-
ment will be resolved through discussion with a third 
reviewer where necessary. Additional information will be 
requested from authors if needed. Review authors will not 
be blinded to the journal titles or study authors. A PRISMA 
(Preferred Reporting Items for Systematic Review and 
Meta-Analysis) flow diagram19 will document the process 
of literature selection and reasons for exclusion.
Each reviewer will extract data independently and in 
duplicate in order to minimise bias and errors, using a 
standardised data extraction tool, which will be piloted 
on the first three eligible texts to ensure its suitability. 
Data will be sought for the following domains:
1. study details: author information, publication year, 
design, sponsorship, geographical location, healthcare 
setting, length of follow-up time if relevant, sampling 
and recruitment methods, period of study, aims and 
objectives
2. population characteristics: for example, mean and 
median age, inclusion and exclusion criteria
3. exposure: definition of eczema as an exposure, num-
ber of exposed subjects, details of eczema severity and 
treatment, age at onset of eczema
4. comparators: definition of unexposed subjects, num-
ber of comparators
5. outcomes: definition and identification of 
cardiovascular outcomes (angina, myocardial 
infarction, coronary revascularisation, heart failure, 
cardiac arrhythmias, stroke and cardiovascular death), 
number of subjects with the outcome.
The definition of eczema that the authors state in 
the original study will be recorded in detail and given 
due consideration in the assessment of study quality. 
We predict that the definition of eczema severity will 
be heterogeneous between studies. For example, severe 
eczema may be defined by the need for systemic treat-
ment; however, this may be a source of misclassification 
bias. Therapeutic agents such as systemic corticosteroids 
may be used for alternative clinical indications, and treat-
ment is an imperfect proxy for defining severity. This 
uncertainty will be dealt with by including a description 
of how authors reported their eczema severity definitions 
in the data extraction stage, by paying particular atten-
tion to definitions of severity in the appraisal of quality 
and in the discussion of the review. Where available, 
unadjusted and fully adjusted effect estimates will be 
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recorded, along with details of confounders. Discrepan-
cies will be resolved by discussion, with a third reviewer 
if necessary.
outcomes
The primary outcome is the association between eczema 
and cardiovascular outcomes, including angina, myocar-
dial infarction, coronary revascularisation, heart failure, 
cardiac arrhythmias, stroke (all subtypes) and cardiovas-
cular death. Where possible, effect estimates will include 
ORs, HRs and incident rate ratios, for cardiovascular 
outcomes in people with eczema compared with those 
without. Secondary outcomes include variation in the 
strength of association between severity of eczema and 
cardiovascular disease, whether the association varies by 
country, and is altered by the treatment of eczema, by 
different cardiovascular disease endpoints, or modified 
by age and gender.
Quality assessment
Critical appraisal will be independently recorded by 
reviewers to allow comparison by study quality. Risk of 
bias will be assessed by considering relevant domains 
to observational studies, including participant selec-
tion, measurement of variables and controlling for 
confounding, in line with the Cochrane Collaboration’s 
Grading of Recommendations Assessment, Development 
and Evaluation (GRADE) tool for assessing risk of bias, 
and the Newcastle-Ottawa Scale, in order to maximise 
relevance to non-randomised studies. Each domain will 
be rated with ‘high’, ‘low’ or ‘unclear’ with regard to the 
risk of bias, with free text explanations. Full results of this 
quality assessment will be included in the resulting review, 
with discussion of quality assessment in the narrative data 
synthesis.
data synthesis
We will group studies by the cardiovascular outcome under 
study and synthesise them narratively. No subgroup anal-
yses are planned. We will only consider information on 
the interaction between eczema and covariates if this has 
been formally assessed in the original publication. We will 
perform meta-analyses on the association between eczema 
and specific cardiovascular outcomes with the help of a 
statistician to obtain a pooled effect estimate. We will assess 
statistical heterogeneity using the I2 statistic. The pooled 
relative risk and its 95% CI will be calculated using random 
effects models. If substantial heterogeneity is observed, we 
will explore the reasons for the heterogeneity in sensitivity 
analyses. Study characteristics and the effect estimates for 
the association between eczema and cardiovascular disease 
will be presented in full, in tabular form. Studies at high risk 
of bias will not be contained in the synthesis. We will look 
for publication bias using standard approaches including 
funnel plots and Egger tests. PRISMA guidelines19 will be 
used to report the results of this study.
ethIcs And dIsseMInAtIon
This systematic review protocol was registered with the Inter-
national Prospective Register of Systematic Reviews (PROS-
PERO) on 22 April 2016. Any amendments to the protocol 
will be documented on the PROSPERO site contemporane-
ously, with full explanation of any change. Ethical approval 
is not required for this study as it is a systematic review. The 
results will be submitted for peer-reviewed publication, and 
for national and international presentation.
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